Clinical trials: Cancer Patient
Colon Cancer
Oral Green Tea Extract and Milk Thistle Extract to Colorectal Cancer Patients Undergoing Resection
Colorectal cancer is the third most common form of cancer found in the United States. To date surgical resection provides the best chance for cure.
- Trial name
- NCT01239095
- Testing
- Green Tea and Milk Thistle Supplements
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Richard Whelan
Metastatic Colorectal Cancer
Study of Bevacizumab in Combination with Alternating XELIRI and XELOX in Metastatic Colorectal Cancer
Open-label, single-arm, phase II study of bevacizumab (AvastinTM) in combination with alternating XELIRI (capecitabine+irinotecan) and XELOX (capecitabine+oxaliplatin) as first-line treatment of patients with metastatic…
- Trial name
- AXOAXI (NCT01531595)
- Testing
- Bevacizumab plus alternating XELOX/XELIRI
- Where
- Finland
- Volunteers
- 100 people
- Sponsor
- Pia Osterlund
Breast Cancer, Estrogen Receptor-positive Breast Cancer
Evaluation of Endocrine Therapy Effects of Host Immunity in Early Stage Breast Cancer
The purpose of this research study is to learn about the effects that standard of care endocrine therapies have on the immune system's response to cancer by looking at the number and types of immune cells present and how they…
- Conditions
- Breast Cancer, Estrogen Receptor-positive Breast Cancer, Healthy
- Trial name
- NCT03719495
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Duke University
Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer
This phase I trial aims to determine if it is safe to use palliative radiotherapy and lurbinectedin at the same time to treat small cell lung cancer that has spread outside of the chest and that has grown after being treated with…
- Trial name
- NCT05244239
- Testing
- Lurbinectedin, Palliative Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Emory University
Non Small Cell Lung Cancer
Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA
The purpose of this study is to evaluate the efficacy of Olmutinib(Olita®) in patients with T790M-positive non-small cell lung cancer (NSCLC) confirmed using DNA extracted from extracellular vesicles of bronchoalveolar lavage…
- Trial name
- NCT03228277
- Testing
- Olmutinib
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- Konkuk University Medical Center
Advanced Solid Tumors
Evaluation of the Safety and Efficacy of Albumin-bound Docetaxel
This trial is an open-label, single-center, dose-escalation and cohort-expansion Phase I clinical study in patients with advanced solid tumors.
- Trial name
- NCT04471675
- Testing
- Albumin-bound docetaxel
- Where
- China
- Volunteers
- 208 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Breast Cancer
Cosmetic and Functional Outcomes After Breast Conserving Surgery
The initial aesthetic and functional conditions are recorded with the help of the Breast Cancer Treatment Outcome Scale (BCTOS),an international validated questionnaire, and the Breast Cancer Conservative Treatment - cosmetic…
- Trial name
- NCT01496001
- Testing
- Lumpectomy, axillary block dissection, breast conserving surgery, Radiotherapy
- Where
- Hungary
- Volunteers
- 300 people
- Sponsor
- National Institute of Oncology, Hungary
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Liposomal Irinotecan, S-1, and Oxaliplatin in Advanced Pancreatic Adenocarcinoma
In present study, the investigators evaluate the safety and efficacy of OIS-derived NASOX regimen (nal-IRI, S-1, oxaliplatin) in advanced pancreatic cancer.
- Trial name
- NASOX (NCT04662112)
- Testing
- NASOX
- Where
- 2 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- Asan Medical Center
Brain and Central Nervous System Tumors
Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma
RATIONALE: Thalidomide and celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00047281
- Testing
- celecoxib, cyclophosphamide, etoposide
- Where
- 3 sites in United States
- Sponsor
- Dana-Farber Cancer Institute
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of gemcitabine, bendamustine, and nivolumab when given together and to see how well they work in treating patients with classic Hodgkin lymphoma that has come back or…
- Conditions
- Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Hodgkin Lymphoma
- Trial name
- NCT03739619
- Testing
- Bendamustine, Gemcitabine, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Emory University
Ovary Cancer
The Effect of Glucose Level and Diabetes Mellitus on Ctrough of Olaparib
Monitored therapy of olaparib concentrations in the blood of diabetic population probably will assess the need for individual dosing of the drug.
- Trial name
- NCT05081765
- Testing
- Lynparza® (AstraZeneca Pharma Poland Sp. z o.o.), Lynparza
- Where
- Poland
- Volunteers
- 40 people
- Sponsor
- Poznan University of Medical Sciences
Giant Cell Tumor of Bone
A Real-world Study on Patients of Unresectable Giant Cell Tumor of Bone
This is a retrospective observational real-world study, which evaluates the efficacy and safety of denosumab and non-denosumab therapies in the treatment of Chinese populations of surgically unsalvageable or severe post-surgery…
- Trial name
- NCT05402865
- Testing
- Denosumab
- Where
- 3 sites in China
- Volunteers
- 301 people
- Sponsor
- Shanghai JMT-Bio Inc.
Pancreatic Cancer
Genistein in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00882765
- Testing
- genistein
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Neuroblastoma, Medulloblastoma
Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer
The purpose of this study is to test the feasibility (ability to be done) of experimental technologies to determine a tumor's molecular makeup (gene expression profile) and mutations.
- Conditions
- Neuroblastoma, Medulloblastoma, Brain Tumors, Rare Tumors
- Trial name
- NCT01802567
- Testing
- Guided Therapy- Pediatric Gene Analysis Platform
- Where
- 13 sites in United States
- Volunteers
- 52 people
- Sponsor
- Giselle Sholler
Glioblastoma Multiforme, Recurrent Glioblastoma
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
- Trial name
- FRONTIER (NCT05303467)
- Testing
- TheraSphere GBM
- Where
- 9 sites in United States
- Volunteers
- 36 people
- Sponsor
- Boston Scientific Corporation
Respiratory Cancer
Resistance Exercise Training For Radically Treated Respiratory Cancer
The first part of the study is an observational part. In eligible patients with early stage respiratory cancer, the primary and secondary endpoints will be evaluated before and after their scheduled radical cancer therapy.
- Trial name
- REINFORCE (NCT00752700)
- Testing
- Conventional resistance training, Whole body vibration resistance training
- Where
- 4 sites in Belgium
- Volunteers
- 113 people
- Sponsor
- University Hospital, Ghent
Fatigue
PG2 Treatment for Improving Fatigue Among Advanced Cancer Patients Under Standard Palliative Care
The objective of this study is to conduct a trial in the spirit of providing as much as possible the benefit of PG2 treatment to eligible patients and to evaluate the efficacy and safety of PG2 for relieving fatigue among…
- Trial name
- NCT00523107
- Testing
- PG2
- Where
- Taiwan
- Volunteers
- 91 people
- Sponsor
- PhytoHealth Corporation
CD7+ Acute Leukemia, CD7+ Lymphoma
Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy
This is a prospective, open-label, single-center clinical trial. This study will evaluate the safety and efficacy of anti-CD7 CAR-T cells in the treatment of relapsed or refractory CD7 positive T-ALL/LBL, T-NHL and AML.
- Trial name
- NCT04599556
- Testing
- anti-CD7 CAR-T
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Zhejiang University
Malignant Melanoma of Skin Stage III, Malignant Melanoma of Skin Stage IV
Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized "Proof-of-principle" Phase II Study
Title: Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-alfa in patients with metastatic melanoma: a randomized…
- Trial name
- ABSIDE (NCT01973322)
- Testing
- arm 1: DC Vaccine + RT, arm 2: DC Vaccine + IFN-alfa, arm 3: both arm 1 and 2 + RT
- Where
- Italy
- Volunteers
- 34 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Vestibular Schwannoma
Response Prediction After GKS in Patients With Vestibular Schwannoma Using DCE MR Imaging
Response Prediction after Gamma Knife Surgery (GKS) in Patients with Vestibular Schwannoma using Dynamic Contrast-Enhanced (DCE) MR Imaging
- Trial name
- NCT03097822
- Volunteers
- 90 people
- Sponsor
- Seoul National University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.